Update and clinical management of anti-DNA auto-antibodies

Anti-deoxyribonucleic acid (DNA) antibodies in the clinical laboratory are intimately linked to the diagnosis and monitoring of systemic lupus erythematosus (SLE); however, the characteristics of the analytical methods and the properties of the antibodies themselves are heterogeneous. To review the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	González Rodríguez Concepción, Aparicio Hernández MªBelén, Alarcón Torres Inmaculada
Formato:	article
Lenguaje:	EN ES
Publicado:	De Gruyter 2021
Materias:	anti-dsdna clinical biomarkers systemic lupus erythematosus Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/2b7faac4bb3948f38f2f5412f818bfbb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2b7faac4bb3948f38f2f5412f818bfbb
record_format	dspace
spelling	oai:doaj.org-article:2b7faac4bb3948f38f2f5412f818bfbb2021-12-05T14:10:39ZUpdate and clinical management of anti-DNA auto-antibodies2628-491X10.1515/almed-2021-0008https://doaj.org/article/2b7faac4bb3948f38f2f5412f818bfbb2021-04-01T00:00:00Zhttps://doi.org/10.1515/almed-2021-0008https://doaj.org/toc/2628-491XAnti-deoxyribonucleic acid (DNA) antibodies in the clinical laboratory are intimately linked to the diagnosis and monitoring of systemic lupus erythematosus (SLE); however, the characteristics of the analytical methods and the properties of the antibodies themselves are heterogeneous. To review the definition and properties of anti-double-stranded anti-DNA (anti-dsDNA) antibodies, the adequacy of analytical methods, and the clinical requirements for this biomarker. Through PubMed we searched the existing literature with the terms anti-dsDNA, editorial, review, guideline, meta-analysis and SLE. The last search, anti-dsDNA and SLE restricted to the last two years. Information was expanded through related articles and those published in official state bodies related to anti-dsDNA and SLE. Clinical laboratory methods for anti-dsDNA analysis and their characteristics are analyze. The clinical utility of anti-dsDNA in its diagnostic, clinical association and follow-up aspects of SLE is reviewed. There is wide variability in analytical methods and deficits in standardization persist. They are part of the current SLE classification criteria and are used as markers in the follow-up of the disease. Their diagnostic usefulness improves when they are determined in antinuclear antibody (ANA)-positive patients. In follow-up, quantification is of interest, preferably with the same analytical method (given the deficits in standardization).González Rodríguez ConcepciónAparicio Hernández MªBelénAlarcón Torres InmaculadaDe Gruyterarticleanti-dsdnaclinical biomarkerssystemic lupus erythematosusMedical technologyR855-855.5ENESAdvances in Laboratory Medicine, Vol 2, Iss 3, Pp 313-321 (2021)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	anti-dsdna clinical biomarkers systemic lupus erythematosus Medical technology R855-855.5
spellingShingle	anti-dsdna clinical biomarkers systemic lupus erythematosus Medical technology R855-855.5 González Rodríguez Concepción Aparicio Hernández MªBelén Alarcón Torres Inmaculada Update and clinical management of anti-DNA auto-antibodies
description	Anti-deoxyribonucleic acid (DNA) antibodies in the clinical laboratory are intimately linked to the diagnosis and monitoring of systemic lupus erythematosus (SLE); however, the characteristics of the analytical methods and the properties of the antibodies themselves are heterogeneous. To review the definition and properties of anti-double-stranded anti-DNA (anti-dsDNA) antibodies, the adequacy of analytical methods, and the clinical requirements for this biomarker. Through PubMed we searched the existing literature with the terms anti-dsDNA, editorial, review, guideline, meta-analysis and SLE. The last search, anti-dsDNA and SLE restricted to the last two years. Information was expanded through related articles and those published in official state bodies related to anti-dsDNA and SLE. Clinical laboratory methods for anti-dsDNA analysis and their characteristics are analyze. The clinical utility of anti-dsDNA in its diagnostic, clinical association and follow-up aspects of SLE is reviewed. There is wide variability in analytical methods and deficits in standardization persist. They are part of the current SLE classification criteria and are used as markers in the follow-up of the disease. Their diagnostic usefulness improves when they are determined in antinuclear antibody (ANA)-positive patients. In follow-up, quantification is of interest, preferably with the same analytical method (given the deficits in standardization).
format	article
author	González Rodríguez Concepción Aparicio Hernández MªBelén Alarcón Torres Inmaculada
author_facet	González Rodríguez Concepción Aparicio Hernández MªBelén Alarcón Torres Inmaculada
author_sort	González Rodríguez Concepción
title	Update and clinical management of anti-DNA auto-antibodies
title_short	Update and clinical management of anti-DNA auto-antibodies
title_full	Update and clinical management of anti-DNA auto-antibodies
title_fullStr	Update and clinical management of anti-DNA auto-antibodies
title_full_unstemmed	Update and clinical management of anti-DNA auto-antibodies
title_sort	update and clinical management of anti-dna auto-antibodies
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/2b7faac4bb3948f38f2f5412f818bfbb
work_keys_str_mv	AT gonzalezrodriguezconcepcion updateandclinicalmanagementofantidnaautoantibodies AT apariciohernandezmabelen updateandclinicalmanagementofantidnaautoantibodies AT alarcontorresinmaculada updateandclinicalmanagementofantidnaautoantibodies
_version_	1718371830558883840

Update and clinical management of anti-DNA auto-antibodies

Ejemplares similares